FDA’s July Warning Letters To Skin-Care Marketers Continue To Surface
This article was originally published in The Rose Sheet
Executive Summary
Add Menscience Androceuticals, La Bella Figura and Healing Scents to the list of skin-care marketers hit with FDA warning letters in July. The agency’s policy is to wait for warning letter recipients to acknowledge receipt before posting the communications to its website.
You may also be interested in...
FDA Warns Enessa For Claims Violations, Diminish-Rosacea Treatment
Natural brand Enessa may have to discontinue or relabel its Diminish-Rosacea Treatment, as the name constitutes an unapproved drug claim, FDA suggests in a warning letter. Other claims cited by the agency pertain to cellular repair, collagen synthesis, anti-inflammatory benefits and improved micro-circulation.
Probiotic Skin Care Could Be Gutsy Move In US Regulatory Environment
Findings that oral probiotics may not only benefit digestive health but also potentially alleviate inflammatory skin disorders are contentious but have driven uptake of probiotic ingredients by cosmetic players. Market opportunity is growing, but probiotic skin-care claims could be liabilities in the US where FDA increasingly has been citing statements about immunotherapeutic and anti-inflammatory effects in warning letters.
FDA Warning Letters Target Skin Brighteners, Muscle-Relaxing Claims
Agency recently posted three warning letters issued to skin-care marketers in August for unapproved drug claims, including statements about reducing muscle contractions for anti-aging effects. All three warnings included a skin-brightening product among items identified as non-compliant on the basis of their claims.